metabolic dysfunction-associated steatotic liver disease
Conditions
Interventions
Non-steatosis group:None
Mild steatosis group:None
Moderate steatosis group:None
Severe steatosis group:None
Sponsors
China-Japan Union Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. Patients with type 2 diabetes; 3. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Exclude specific liver diseases that can lead to fatty liver, such as alcoholic liver disease, genotype 3 hepatitis C virus infection, autoimmune hepatitis, and Wilson's disease; 2. Exclude special conditions that can cause fatty liver, including drugs (tamoxifen, amiodarone, valproate, methotrexate, glucocorticoids, etc.), total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing's syndrome, ß-lipoprotein deficiency, lipodystrophic diabetes, and Mauriac syndrome; 3. Exclude acute and chronic kidney disease and renal failure; 4. Exclude patients who have undergone cholecystectomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultrasound-Derived Fat Fraction;Magnetic Resonance Imaging Proton Density Fat Fraction;Controlled Attenuation Parameter; | — |
Countries
China
Contacts
Public ContactSun Zhixia
China-Japan Union Hospital of Jilin University
Outcome results
None listed